Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolametinib versus investigator's choice chemotherapy in previously immunotherapy-treated NRAS-mutant advanced melanoma
CTR20231948Phase 3Active
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tunlametinib in melanoma, sponsored by Shanghai KeChow Pharmaceuticals. Started Nov 2023; status: active.
02
Drugs
tunlametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20231948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231948.